| JNPMEDI Becomes a Platinum Member of the Clinical Data Interchange Standards Consortium (CDISC)
| Ensures Clinical Trial Results Compliant with International Standards through 'Maven Clinical Cloud'
| Aims to Expand Clinical Trial Data Services Utilizing CDISC Standards, Leading to Greater Efficiency
Healthcare data platform company JNPMEDI (CEO Kwunho Jeong) announced on the 7th that it has acquired Platinum Membership in the Clinical Data Interchange Standards Consortium (CDISC).
CDISC is an international non-profit organization that defines standard formats for clinical trial data. Regulatory agencies in the U.S. (FDA), Europe (EMA), and Japan (PMDA) mandate the application of CDISC standards for the approval processes of new drugs, medical devices, and medical technologies, requiring clinical data to be managed according to these standards. Consequently, global pharmaceutical companies and research institutions submit clinical trial data to regulatory agencies in compliance with CDISC standards.
JNPMEDI's acquisition of CDISC Platinum Membership signifies its capability to operate clinical trials based on CDISC standards, ensuring that customers receive clinical trial results that meet international standards. With this, customers using JNPMEDI's 'Maven Clinical Cloud' can manage data according to international standards at a reasonable cost.
The Maven Clinical Cloud is a Software-as-a-Service (SaaS) solution that allows users to select only the services they need. It is designed to manage and analyze clinical trial data efficiently, leveraging CDISC's international clinical data standards.
Furthermore, JNPMEDI plans to participate as a Platinum Member in CDISC Interchange events held in Korea, the U.S., Europe, and Japan. Notably, at the 2023 US Interchange in October, JNPMEDI will have a solo booth to showcase its solutions to global customers.
JNPMEDI CEO Kwunho Jeong stated, "As CDISC becomes an essential element in the digitization of clinical trial data, the demand for compliant submissions is increasing. We expect that obtaining CDISC Platinum Membership will accelerate the global standardization of the Maven Clinical Cloud and expand our service areas."
| JNPMEDI Becomes a Platinum Member of the Clinical Data Interchange Standards Consortium (CDISC)
| Ensures Clinical Trial Results Compliant with International Standards through 'Maven Clinical Cloud'
| Aims to Expand Clinical Trial Data Services Utilizing CDISC Standards, Leading to Greater Efficiency
Healthcare data platform company JNPMEDI (CEO Kwunho Jeong) announced on the 7th that it has acquired Platinum Membership in the Clinical Data Interchange Standards Consortium (CDISC).
CDISC is an international non-profit organization that defines standard formats for clinical trial data. Regulatory agencies in the U.S. (FDA), Europe (EMA), and Japan (PMDA) mandate the application of CDISC standards for the approval processes of new drugs, medical devices, and medical technologies, requiring clinical data to be managed according to these standards. Consequently, global pharmaceutical companies and research institutions submit clinical trial data to regulatory agencies in compliance with CDISC standards.
JNPMEDI's acquisition of CDISC Platinum Membership signifies its capability to operate clinical trials based on CDISC standards, ensuring that customers receive clinical trial results that meet international standards. With this, customers using JNPMEDI's 'Maven Clinical Cloud' can manage data according to international standards at a reasonable cost.
The Maven Clinical Cloud is a Software-as-a-Service (SaaS) solution that allows users to select only the services they need. It is designed to manage and analyze clinical trial data efficiently, leveraging CDISC's international clinical data standards.
Furthermore, JNPMEDI plans to participate as a Platinum Member in CDISC Interchange events held in Korea, the U.S., Europe, and Japan. Notably, at the 2023 US Interchange in October, JNPMEDI will have a solo booth to showcase its solutions to global customers.
JNPMEDI CEO Kwunho Jeong stated, "As CDISC becomes an essential element in the digitization of clinical trial data, the demand for compliant submissions is increasing. We expect that obtaining CDISC Platinum Membership will accelerate the global standardization of the Maven Clinical Cloud and expand our service areas."